MedTrace Logo

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT05597306 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-01-08

No results posted yet for this study

Summary

This study aims to learn about the safety, tolerability, and different dose levels' safety profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with relapsed or refractory acute myeloid leukemia.

Conditions

Interventions

DRUG

Venetoclax

Venetoclax will be administered orally once daily via tablet.

DRUG

Bomedemstat

Bomedemstat will be administered orally once daily via capsule.

Sponsors & Collaborators

  • Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

    collaborator INDUSTRY

  • Terrence J Bradley, MD

    lead OTHER

Principal Investigators

  • Terrence J Bradley, MD · University of Miami

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-19
Primary Completion
2026-11-19
Completion
2026-11-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05597306 on ClinicalTrials.gov